Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$13.97
+7.2%
$13.38
$9.57
$30.41
$1.92B0.891.46 million shs2.07 million shs
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$70.47
+2.7%
$67.57
$60.56
$82.49
$8.58B0.871.63 million shs1.56 million shs
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$7.16
+2.1%
$8.08
$6.07
$21.02
$552.76M1.381.12 million shs1.17 million shs
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$31.33
$31.22
$19.45
$31.79
$2.77B0.731.24 million shsN/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+7.38%-0.07%+18.49%-26.05%-36.73%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
+2.61%+5.84%+9.32%-9.05%-3.87%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
+1.92%-11.72%+3.70%-15.00%-61.59%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.00%0.00%+1.36%+0.97%+23.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.5581 of 5 stars
3.31.00.03.43.12.50.0
Henry Schein, Inc. stock logo
HSIC
Henry Schein
3.3363 of 5 stars
2.33.00.03.42.02.50.6
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
4.7939 of 5 stars
3.02.00.03.92.63.33.8
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.9961 of 5 stars
1.03.02.51.70.01.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.67
Moderate Buy$43.25209.59% Upside
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.64
Moderate Buy$79.3012.53% Upside
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
2.00
Hold$12.5074.70% Upside
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
2.09
Hold$26.57-15.19% Downside

Current Analyst Ratings Breakdown

Latest PDCO, OMI, HSIC, and ARWR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$80.00 ➝ $75.00
5/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$90.00 ➝ $86.00
4/30/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$83.00 ➝ $77.00
4/17/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $11.00
3/10/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$14.00 ➝ $10.00
3/3/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$10.00 ➝ $11.00
2/26/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$83.00 ➝ $80.00
2/26/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$90.00 ➝ $90.00
2/25/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.00
2/14/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$51.00 ➝ $38.00
2/14/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$80.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$2.50M767.33N/AN/A$1.54 per share9.07
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$12.67B0.68$6.03 per share11.68$33.01 per share2.13
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$10.70B0.05$5.72 per share1.25$12.08 per share0.59
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$6.51B0.43$3.42 per share9.17$11.18 per share2.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$599.49M-$5.17N/AN/AN/AN/A-236.60%-64.09%N/A
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$416M$3.2029.0014.042.132.51%12.90%5.21%N/A
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
-$41.30M-$4.75N/A4.070.20-0.46%14.60%2.51%8/1/2025 (Estimated)
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$185.93M$1.5418.3212.842.712.37%19.77%6.66%6/17/2025 (Estimated)

Latest PDCO, OMI, HSIC, and ARWR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q2 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million
5/10/2025Q1 2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.20$0.23+$0.03N/AN/AN/A
5/8/2025Q1 2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.20$0.23+$0.03-$0.32$2.66 billion$2.63 billion
5/5/2025Q1 2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$1.11$1.15+$0.04$0.88$3.24 billion$3.17 billion
2/28/2025Q4 2024
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.53$0.55+$0.02-$3.84$2.68 billion$2.70 billion
2/25/2025Q4 2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$1.23$1.19-$0.04$0.74$3.25 billion$3.19 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Henry Schein, Inc. stock logo
HSIC
Henry Schein
N/AN/AN/AN/AN/A
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
N/AN/AN/AN/AN/A
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$1.043.32%N/A67.53%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
7.27
6.09
6.09
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.46
1.42
0.82
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
2.11
1.09
0.45
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.34
1.37
0.76

Institutional Ownership

CompanyInstitutional Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
96.62%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
98.04%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
85.43%

Insider Ownership

CompanyInsider Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
4.30%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
1.08%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
3.69%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400137.32 million120.68 millionOptionable
Henry Schein, Inc. stock logo
HSIC
Henry Schein
22,000121.72 million123.26 millionOptionable
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
22,50077.26 million74.34 millionOptionable
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
7,70088.47 million86.64 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$13.97 +0.94 (+7.21%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$15.00 +1.04 (+7.41%)
As of 08:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Henry Schein stock logo

Henry Schein NASDAQ:HSIC

$70.47 +1.83 (+2.67%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$69.09 -1.38 (-1.96%)
As of 06:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Owens & Minor stock logo

Owens & Minor NYSE:OMI

$7.16 +0.15 (+2.07%)
Closing price 05/12/2025 03:59 PM Eastern
Extended Trading
$7.11 -0.04 (-0.61%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Owens & Minor, Inc. is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments. The Products and Healthcare Services segment includes medical distribution, the outsourced logistics and value-added services business, and global products, which manufacture and source medical surgical products through the production and kitting operations. The Patient Direct segment includes the home healthcare business, Byram and Apria. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Henrico County, VA.

Patterson Companies stock logo

Patterson Companies NASDAQ:PDCO

$31.33 0.00 (0.00%)
As of 04/17/2025

Patterson Companies, Inc. engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.